Table of Content

Open Access iconOpen Access

ERRATUM

Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells

Dong Li*1, Fei-fan Sun*1, Dan Wang*1,Tao Wang*, Jing-jing Peng*, Jian-Qiong Feng*, Hua Li*, Chao Wang, Dai-jun Zhou*, Hong Luo*, Zeng-qiang Fu*, Tao Zhang*

* Department of Oncology, The General Hospital of Western Theater Command, Chengdu, P.R. China
† Department of Pathology, The General Hospital of Western Theater Command, Chengdu, P.R. China

Oncology Research 2020, 28(7-8), 827-828. https://doi.org/10.3727/096504021X16280937554409

Abstract

Sorafenib, a multityrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC), but the clinical response to sorafenib is seriously limited by drug resistance. Programmed death ligand-1 (PD-L1) is one of the most important inhibitory molecules involved in tumor immune evasion. Recently, it has been reported that PD-L1 could play crucial roles in drug resistance of many kinds of cancers. However, the expression, function, and regulation of PD-L1 in sorafenib-resistant hepatoma cells remain unclear. In this study, we reported that PD-L1 was overexpressed in sorafenib-resistant hepatoma cells, and shRNA-mediated PD-L1 depletion attenuated drug resistance and suppressed the migration, invasion, colony formation, and tumorigenesis in sorafenib-resistant hepatoma cells in vitro and in vivo. Mechanistic investigations indicated that loss of microRNA-1 (miR-1), a tumor-suppressive microRNA, contributed to the PD-L1 upregulation in sorafenib-resistant hepatoma cells, and PD-L1 was a direct regulatory target of miR-1. Further study revealed that an oncogenic transcriptional factor, nuclear factor E2-related factor 2 (NRF-2), was induced in sorafenibresistant hepatoma cells and inhibited expression of miR-1 in vitro. From molecular mechanism insight back to the functional verification, we eventually demonstrated that miR-1 executed its tumor-suppressive effects on drug resistance and other malignant properties in sorafenib-resistant hepatoma cells partially by PD-L1 inhibition in vitro and in vivo. In conclusion, our data suggested that a NRF-2/miR-1/PD-L1 regulatory axis contributed to the development and maintenance of drug resistance and other tumorigenic properties in sorafenib-resistant hepatoma cells and provided a potential therapeutic target for overcoming sorafenib resistance in HCC.

Keywords


Cite This Article

APA Style
Li, D., Sun, F., Wang, D., Wang, T., Peng, J. et al. (2020). Programmed death ligand-1 (PD-L1) regulated by nrf-2/microrna-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells. Oncology Research, 28(7-8), 827-828. https://doi.org/10.3727/096504021X16280937554409
Vancouver Style
Li D, Sun F, Wang D, Wang T, Peng J, Feng J, et al. Programmed death ligand-1 (PD-L1) regulated by nrf-2/microrna-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells. Oncol Res. 2020;28(7-8):827-828 https://doi.org/10.3727/096504021X16280937554409
IEEE Style
D. Li et al., "Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells," Oncol. Res., vol. 28, no. 7-8, pp. 827-828. 2020. https://doi.org/10.3727/096504021X16280937554409



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 539

    View

  • 381

    Download

  • 0

    Like

Share Link